BlackRock Investment Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

BlackRock Investment Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$481K	Buy	22,050 +183	+0.8%	+$4.63K	﹤0.01%	3062
2016 Q3	$576K	Sell	21,867 -59	-0.3%	-$1.17K	﹤0.01%	2975
2016 Q2	$433K	Buy	+21,926	New	+$426K	﹤0.01%	3127

Other funds holding RETA

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Investment Management's RETA Position: Q4 2016 in Review

BlackRock Investment Management increased its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) stake by 0.84% in Q4 2016, buying an estimated $4.63K and bringing the position to 22,050 shares worth $481K. The position accounts for ﹤0.01% of the portfolio, ranked #3062.

BlackRock Investment Management first reported a position in RETA in Q2 2016 and has held it in 3 quarters since. The position peaked at $576K in Q3 2016. 52 funds tracked by Wall St. Rank hold RETA as of Q4 2016.

BlackRock Investment Management held 22,050 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $481K as of Q4 2016.
BlackRock Investment Management bought 183 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2016, an estimated $4.63K.
Reata Pharmaceuticals, Inc. Class A Common Stock made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3062 holding.
BlackRock Investment Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and has held it in 3 quarters since.
BlackRock Investment Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $576K in Q3 2016.
52 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.